AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. NAGE
  4. [Form 4] Niagen Bioscience, Inc. Insider Trading Activity

[Form 4] Niagen Bioscience, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Niagen Bioscience (NAGE) Director Kristin Patrick received a stock option grant for 20,000 shares of common stock on June 24, 2025. The options were granted with the following terms:

  • Exercise price set at $14.13 per share
  • 100% vesting scheduled for June 24, 2026
  • Options expire on June 23, 2035
  • Total grant value will be determined by stock price appreciation above $14.13

The Form 4 filing was signed by Attorney-in-Fact Jeong James Lee on June 26, 2025. This equity compensation grant appears to be part of the company's director compensation program, providing long-term alignment with shareholder interests through a 10-year exercise window following the one-year cliff vesting period.

Kristin Patrick, direttore di Niagen Bioscience (NAGE), ha ricevuto una concessione di opzioni su azioni per 20.000 azioni ordinarie il 24 giugno 2025. Le opzioni sono state assegnate con le seguenti condizioni:

  • Prezzo di esercizio fissato a $14,13 per azione
  • 100% di maturazione prevista per il 24 giugno 2026
  • Le opzioni scadono il 23 giugno 2035
  • Il valore totale della concessione sar脿 determinato dall'apprezzamento del prezzo delle azioni oltre i $14,13

Il modulo Form 4 猫 stato firmato dall鈥橝ttorney-in-Fact Jeong James Lee il 26 giugno 2025. Questa concessione di compensi in equity sembra far parte del programma di compensazione dei direttori della societ脿, garantendo un allineamento a lungo termine con gli interessi degli azionisti attraverso una finestra di esercizio di 10 anni dopo un periodo di maturazione iniziale di un anno.

Kristin Patrick, directora de Niagen Bioscience (NAGE), recibi贸 una concesi贸n de opciones sobre acciones por 20,000 acciones ordinarias el 24 de junio de 2025. Las opciones se otorgaron con los siguientes t茅rminos:

  • Precio de ejercicio establecido en $14.13 por acci贸n
  • 100% de adquisici贸n programada para el 24 de junio de 2026
  • Las opciones expiran el 23 de junio de 2035
  • El valor total de la concesi贸n depender谩 de la apreciaci贸n del precio de las acciones por encima de $14.13

El formulario Form 4 fue firmado por el apoderado Jeong James Lee el 26 de junio de 2025. Esta concesi贸n de compensaci贸n en acciones parece ser parte del programa de compensaci贸n para directores de la compa帽铆a, proporcionando una alineaci贸n a largo plazo con los intereses de los accionistas mediante una ventana de ejercicio de 10 a帽os tras un per铆odo inicial de adquisici贸n de un a帽o.

Niagen Bioscience (NAGE) 鞚挫偓鞚� Kristin Patrick電� 2025雲� 6鞗� 24鞚检棎 氤错喌欤� 20,000欤�鞐� 雽�頃� 欤检嫕毵れ垬靹犿儩甓岇潉 氚涭晿鞀惦媹雼�. 鞓奠厴鞚� 雼れ潓瓿� 臧欖潃 臁瓣贝鞙茧 攵�鞐悩鞐堨姷雼堧嫟:

  • 頄夓偓臧�瓴╈潃 欤茧嫻 $14.13搿� 靹れ爼
  • 100% 甓岆Μ頇曥爼鞚检潃 2026雲� 6鞗� 24鞚�
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 23鞚�
  • 齑� 攵�鞐� 臧�旃橂姅 $14.13 鞚挫儊鞚� 欤缄皜 靸侅姽鞐� 霐半澕 瓴办爼

Form 4 鞝滌稖 靹滊電� 2025雲� 6鞗� 26鞚� 雽�毽澑鞚� Jeong James Lee臧� 靹滊獏頄堨姷雼堧嫟. 鞚� 欤检嫕 氤挫儊 攵�鞐姅 須岇偓鞚� 鞚挫偓 氤挫儊 頂勲攴鸽灗鞚� 鞚茧秬搿� 氤挫澊氅�, 1雲� 甓岆Μ頇曥爼 旮瓣皠 頉� 10雲勱皠 頄夓偓 臧�電ロ暅 旮瓣皠鞚� 韱淀暣 欤检＜ 鞚挫澋瓿� 鞛リ赴鞝侅溂搿� 鞚检箻鞁滍偆電� 甑“鞛呺媹雼�.

Kristin Patrick, administratrice de Niagen Bioscience (NAGE), a re莽u une attribution d鈥檕ptions d鈥檃chat de 20 000 actions ordinaires le 24 juin 2025. Les options ont 茅t茅 accord茅es selon les conditions suivantes :

  • Prix d鈥檈xercice fix茅 脿 14,13 $ par action
  • Acquisition totale pr茅vue pour le 24 juin 2026
  • Les options expirent le 23 juin 2035
  • La valeur totale de l鈥檃ttribution d茅pendra de l鈥檃ppr茅ciation du cours de l鈥檃ction au-del脿 de 14,13 $

Le formulaire 4 a 茅t茅 sign茅 par le mandataire Jeong James Lee le 26 juin 2025. Cette attribution de r茅mun茅ration en actions semble faire partie du programme de r茅mun茅ration des administrateurs de la soci茅t茅, assurant une alignement 脿 long terme avec les int茅r锚ts des actionnaires gr芒ce 脿 une p茅riode d鈥檈xercice de 10 ans apr猫s une p茅riode d鈥檃cquisition avec cliff d鈥檜n an.

Kristin Patrick, Direktorin von Niagen Bioscience (NAGE), erhielt am 24. Juni 2025 eine Zuteilung von Aktienoptionen f眉r 20.000 Stammaktien. Die Optionen wurden zu folgenden Bedingungen gew盲hrt:

  • Aus眉bungspreis von $14,13 pro Aktie
  • 100%ige Vesting-Regelung zum 24. Juni 2026
  • Optionen verfallen am 23. Juni 2035
  • Der Gesamtwert der Zuteilung wird durch die Kurssteigerung 眉ber $14,13 hinaus bestimmt

Das Form-4-Dokument wurde am 26. Juni 2025 vom Bevollm盲chtigten Jeong James Lee unterzeichnet. Diese Aktienverg眉tung scheint Teil des Verg眉tungsprogramms f眉r Direktoren des Unternehmens zu sein und sorgt f眉r eine langfristige Ausrichtung an den Interessen der Aktion盲re durch ein Aus眉bungsfenster von 10 Jahren nach einer einj盲hrigen Cliff-Vesting-Periode.

Positive
  • None.
Negative
  • None.

Kristin Patrick, direttore di Niagen Bioscience (NAGE), ha ricevuto una concessione di opzioni su azioni per 20.000 azioni ordinarie il 24 giugno 2025. Le opzioni sono state assegnate con le seguenti condizioni:

  • Prezzo di esercizio fissato a $14,13 per azione
  • 100% di maturazione prevista per il 24 giugno 2026
  • Le opzioni scadono il 23 giugno 2035
  • Il valore totale della concessione sar脿 determinato dall'apprezzamento del prezzo delle azioni oltre i $14,13

Il modulo Form 4 猫 stato firmato dall鈥橝ttorney-in-Fact Jeong James Lee il 26 giugno 2025. Questa concessione di compensi in equity sembra far parte del programma di compensazione dei direttori della societ脿, garantendo un allineamento a lungo termine con gli interessi degli azionisti attraverso una finestra di esercizio di 10 anni dopo un periodo di maturazione iniziale di un anno.

Kristin Patrick, directora de Niagen Bioscience (NAGE), recibi贸 una concesi贸n de opciones sobre acciones por 20,000 acciones ordinarias el 24 de junio de 2025. Las opciones se otorgaron con los siguientes t茅rminos:

  • Precio de ejercicio establecido en $14.13 por acci贸n
  • 100% de adquisici贸n programada para el 24 de junio de 2026
  • Las opciones expiran el 23 de junio de 2035
  • El valor total de la concesi贸n depender谩 de la apreciaci贸n del precio de las acciones por encima de $14.13

El formulario Form 4 fue firmado por el apoderado Jeong James Lee el 26 de junio de 2025. Esta concesi贸n de compensaci贸n en acciones parece ser parte del programa de compensaci贸n para directores de la compa帽铆a, proporcionando una alineaci贸n a largo plazo con los intereses de los accionistas mediante una ventana de ejercicio de 10 a帽os tras un per铆odo inicial de adquisici贸n de un a帽o.

Niagen Bioscience (NAGE) 鞚挫偓鞚� Kristin Patrick電� 2025雲� 6鞗� 24鞚检棎 氤错喌欤� 20,000欤�鞐� 雽�頃� 欤检嫕毵れ垬靹犿儩甓岇潉 氚涭晿鞀惦媹雼�. 鞓奠厴鞚� 雼れ潓瓿� 臧欖潃 臁瓣贝鞙茧 攵�鞐悩鞐堨姷雼堧嫟:

  • 頄夓偓臧�瓴╈潃 欤茧嫻 $14.13搿� 靹れ爼
  • 100% 甓岆Μ頇曥爼鞚检潃 2026雲� 6鞗� 24鞚�
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 23鞚�
  • 齑� 攵�鞐� 臧�旃橂姅 $14.13 鞚挫儊鞚� 欤缄皜 靸侅姽鞐� 霐半澕 瓴办爼

Form 4 鞝滌稖 靹滊電� 2025雲� 6鞗� 26鞚� 雽�毽澑鞚� Jeong James Lee臧� 靹滊獏頄堨姷雼堧嫟. 鞚� 欤检嫕 氤挫儊 攵�鞐姅 須岇偓鞚� 鞚挫偓 氤挫儊 頂勲攴鸽灗鞚� 鞚茧秬搿� 氤挫澊氅�, 1雲� 甓岆Μ頇曥爼 旮瓣皠 頉� 10雲勱皠 頄夓偓 臧�電ロ暅 旮瓣皠鞚� 韱淀暣 欤检＜ 鞚挫澋瓿� 鞛リ赴鞝侅溂搿� 鞚检箻鞁滍偆電� 甑“鞛呺媹雼�.

Kristin Patrick, administratrice de Niagen Bioscience (NAGE), a re莽u une attribution d鈥檕ptions d鈥檃chat de 20 000 actions ordinaires le 24 juin 2025. Les options ont 茅t茅 accord茅es selon les conditions suivantes :

  • Prix d鈥檈xercice fix茅 脿 14,13 $ par action
  • Acquisition totale pr茅vue pour le 24 juin 2026
  • Les options expirent le 23 juin 2035
  • La valeur totale de l鈥檃ttribution d茅pendra de l鈥檃ppr茅ciation du cours de l鈥檃ction au-del脿 de 14,13 $

Le formulaire 4 a 茅t茅 sign茅 par le mandataire Jeong James Lee le 26 juin 2025. Cette attribution de r茅mun茅ration en actions semble faire partie du programme de r茅mun茅ration des administrateurs de la soci茅t茅, assurant une alignement 脿 long terme avec les int茅r锚ts des actionnaires gr芒ce 脿 une p茅riode d鈥檈xercice de 10 ans apr猫s une p茅riode d鈥檃cquisition avec cliff d鈥檜n an.

Kristin Patrick, Direktorin von Niagen Bioscience (NAGE), erhielt am 24. Juni 2025 eine Zuteilung von Aktienoptionen f眉r 20.000 Stammaktien. Die Optionen wurden zu folgenden Bedingungen gew盲hrt:

  • Aus眉bungspreis von $14,13 pro Aktie
  • 100%ige Vesting-Regelung zum 24. Juni 2026
  • Optionen verfallen am 23. Juni 2035
  • Der Gesamtwert der Zuteilung wird durch die Kurssteigerung 眉ber $14,13 hinaus bestimmt

Das Form-4-Dokument wurde am 26. Juni 2025 vom Bevollm盲chtigten Jeong James Lee unterzeichnet. Diese Aktienverg眉tung scheint Teil des Verg眉tungsprogramms f眉r Direktoren des Unternehmens zu sein und sorgt f眉r eine langfristige Ausrichtung an den Interessen der Aktion盲re durch ein Aus眉bungsfenster von 10 Jahren nach einer einj盲hrigen Cliff-Vesting-Periode.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Patrick Kristin
(Last) (First) (Middle)
10900 WILSHIRE BLVD. SUITE 600
(Street)
LOS ANGELES CA 90024
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $14.13 06/24/2025 A 20,000 06/24/2026(1) 06/23/2035 Common Stock 20,000 $0 20,000 D
Explanation of Responses:
1. Option vests 100% on June 24, 2026.
Remarks:
/s/ Jeong James Lee, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options did NAGE director Kristin Patrick receive on June 24, 2025?

According to the Form 4 filing, NAGE director Kristin Patrick received 20,000 stock options with an exercise price of $14.13 per share. These options were granted on June 24, 2025, will vest 100% on June 24, 2026, and expire on June 23, 2035.

When do Kristin Patrick's NAGE stock options vest?

The stock options granted to Kristin Patrick will vest 100% on June 24, 2026, as indicated in the Form 4 filing's explanatory notes.

What is the exercise price of NAGE stock options granted to director Kristin Patrick?

The stock options were granted with an exercise price of $14.13 per share, as reported in the Form 4 filing dated June 28, 2025.

How many NAGE stock options does Kristin Patrick beneficially own after the June 24, 2025 grant?

Following the reported transaction, Kristin Patrick beneficially owns 20,000 stock options of NAGE directly (indicated by 'D' in the ownership form column).

What position does Kristin Patrick hold at NAGE?

According to the Form 4 filing, Kristin Patrick serves as a Director of Niagen Bioscience, Inc. (NAGE), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.
Stock NAGE logo
Niagen Bioscience, Inc

NASDAQ:NAGE

NAGE Rankings

#3992 Ranked by Market Cap
N/A Ranked by Dividends

NAGE Latest News

Aug 6, 2025
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook
Aug 6, 2025
Adeia Wins Best of Show Award at FMS: The Future of Memory and Storage Conference
Aug 4, 2025
Niagen Bioscience to Present at Canaccord Genuity鈥檚 45th Annual Growth Conference
Jul 23, 2025
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Jul 14, 2025
Niagen Bioscience Announces the Debut of Tru Niagen庐 and Niagen IV at Equinox Hotel New York

NAGE Latest SEC Filings

Aug 6, 2025
[8-K] Niagen Bioscience, Inc. Reports Material Event
Jul 29, 2025
[8-K] Niagen Bioscience, Inc. Reports Material Event
Jul 3, 2025
[Form 4] Niagen Bioscience, Inc. Insider Trading Activity
Jun 27, 2025
[8-K] Niagen Bioscience, Inc. Reports Material Event
Jun 26, 2025
[Form 4] Niagen Bioscience, Inc. Insider Trading Activity

NAGE Stock Data

721.53M
51.64M
34.44%
33.26%
4.43%
Biotechnology
Medicinal Chemicals & Botanical Products
United States
LOS ANGELES